Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirtobrutinib in adults with immune thrombocytopenia
2024-518502-40-00Phase 2Authorised
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 2 trial of pirtobrutinib in immune thrombocytopenia (ITP) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Dose-limiting toxicities, Safety endpoints and 1 more. Planned start Jul 2025; status: authorised.
02
Drugs
pirtobrutinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2024-518502-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518502-40-00.